SCHEMBL1612926

SCHEMBL1612926

CC(=O)c1c[nH]c2ccc(Br)cc12

nearest known ligand 0.69

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 1/20 0.69
PBRM1 Q86U86 1/20 0.59
GABRA1 P14867 1/20 0.56
GABRB1 P18505 1/20 0.56
GABRA3 P34903 1/20 0.56
GABRB2 P47870 1/20 0.56
KDM4E B2RXH2 1/20 0.54
HSD17B10 Q99714 1/20 0.54
MTNR1A P48039 1/20 0.54
MTNR1B P49286 1/20 0.54
GPR84 Q9NQS5 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
HASPIN Q8TF76 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29781910 0.86 PBRM1 (0.59) NR4A2PBRM1GABRA1GABRB1GABRA3
SCHEMBL17023350 0.86 PBRM1 (0.59) NR4A2PBRM1GABRA1GABRB1GABRA3
SCHEMBL5434549 0.86 NR4A2 (0.69) NR4A2GABRA1GABRB1GABRA3GABRB2
SCHEMBL2085712 0.86 NR4A2 (0.69) NR4A2GABRA1GABRB1GABRA3GABRB2
SCHEMBL16429179 0.84 NR4A2 (0.62) NR4A2GABRA1GABRB1GABRA3GABRB2
SCHEMBL14646062 0.83 NR4A2 (0.60) NR4A2GABRA1GABRB1GABRA3GABRB2
SCHEMBL17829923 0.83 NR4A2 (0.65) NR4A2GABRA1GABRB1GABRA3GABRB2
SCHEMBL4685934 0.83 NR4A2 (0.65) NR4A2GABRA1GABRB1GABRA3GABRB2
SCHEMBL23227885 0.82 NR4A2 (0.68) NR4A2GABRA1GABRB1GABRA3GABRB2
SCHEMBL24143309 0.82 NR4A2 (0.64) NR4A2GABRA1GABRB1GABRA3GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12485109-B2 Pyrrolo 12.3-dipyrimidine compounds and analogues thereof BIOCRYST PHARMACEUTICALS, INC. (US) 2025-12-02 US disclosed
US-12338230-B2 Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders ACHILLION PHARMACEUTICALS, INC. (US) 2025-06-24 US disclosed
EP-4129407-B1 ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS ACHILLION PHARMACEUTICALS INC (US) 2024-12-25 EP disclosed
US-12139497-B2 Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders ACHILLION PHARMACEUTICALS, INC. (US) 2024-11-12 US disclosed
US-12065459-B2 Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders ACHILLION PHARMACEUTICALS, INC. (US) 2024-08-20 US disclosed
US-20240199583-A1 ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS ACHILLION PHARMACEUTICALS, INC. 2024-06-20 US disclosed
EP-3925956-B1 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS BIOCRYST PHARM INC (US) 2024-04-10 EP disclosed
US-11926617-B2 Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders ACHILLION PHARMACEUTICALS, INC. (US) 2024-03-12 US disclosed
EP-3340983-B1 ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS ACHILLION PHARMACEUTICALS INC (US) 2023-10-04 EP disclosed
EP-3340983-B1 ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS ACHILLION PHARMACEUTICALS INC (US) 2023-10-04 EP disclosed
CN-102093341-A Indole ring substituted pyrazole carboxylic acid endothelin receptor antagonist as well as preparation method and application thereof TIANJIN INST PHARM RESEARCH 2011-06-15 CN disclosed
EP-2315751-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS Amgen Inc. (US) 2011-05-04 EP disclosed
US-20110086834-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2011-04-14 US disclosed
US-20110086834-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2011-04-14 US disclosed
US-20110086834-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2011-04-14 US disclosed
WO-2009158011-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2009-12-30 WO disclosed
WO-2009158011-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2009-12-30 WO disclosed
US-20070149514-A1 Indole-phenylsulfonamide derivatives used as ppar-delta activating compounds BAYER HEALTHCARE AG (DE) 2007-06-28 US disclosed
EP-1583743-A1 INDOLE-PHENYLSULFONAMIDE DERIVATIVES USED AS PPAR-DELTA ACTIVATING COMPOUNDS Bayer HealthCare AG (DE) 2005-10-12 EP disclosed
WO-2004060871-A1 INDOLE-PHENYLSULFONAMIDE DERIVATIVES USED AS PPAR-DELTA ACTIVATING COMPOUNDS BAYER HEALTHCARE AG (DE) 2004-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12485109-B2 Pyrrolo 12.3-dipyrimidine compounds and analogues thereof C5, DPYD, C9 NR4A2 3418/4885PBRM1 1445/4885GABRA1 4252/4885
US-12065459-B2 Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders TFPI, CFD, F3 NR4A2 587/4885PBRM1 4674/4885GABRA1 3733/4885
US-12338230-B2 Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders CFD, TFPI, CFH NR4A2 895/4885PBRM1 3973/4885GABRA1 3076/4885
US-20110086834-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS NFKBIA, MAP3K1, MAP3K2 NR4A2 889/4885PBRM1 2884/4885GABRA1 3322/4885
US-20240199583-A1 ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS CFD, TFPI, CFH NR4A2 895/4885PBRM1 3973/4885GABRA1 3076/4885
US-11926617-B2 Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders CFD, TFPI, CFH NR4A2 895/4885PBRM1 3973/4885GABRA1 3076/4885
US-20070149514-A1 Indole-phenylsulfonamide derivatives used as ppar-delta activating compounds PPARD, PPARA, PPARG NR4A2 304/4885PBRM1 4382/4885GABRA1 1965/4885
US-12139497-B2 Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders CFD, F12, F3 NR4A2 962/4885PBRM1 3910/4885GABRA1 3683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.